LATEST NEWS

View all +
  • ITPC Launches 2015-2017 Strategic Plan

    Following an intensive period of internal reflection and external review, ITPC is proud to present our new strategic plan. The new plan will guide our work over the next three years and outlines....

BLOG: VOICES FROM ACTIVISTS

View all +
  • "We are the doctors!"

    And this is exactly what ITPC has been advocating for at global level for so many years: for treatment programmes to work in the long run, you need to support community-initiated and -run treatment education projects...
  • Why I’ll keep showing up to protest Gilead’s pricing on Hepatitis C drugs

    We knew it wasn’t going to be easy to protest at the recent Gilead Press Conference in New Delhi, held on 15th September 2014. The press conference was in a posh, five-star hotel. So we thought we’d do a silent protest, to get our message across to Gilead, Indian pharmaceutical companies and the local press that Gilead’s refusal to allow generic versions of the drug Solvadi (which can cure Hepatitis C) in some countries is unacceptable. We were a group of local activists, from across organizations in India, numbering about 10 people. When we arrived at the hotel, we found the press conference room and set-up the protest at the entrance. We pulled out a large banner, and sat down at the main entrance gate. We did not shout or make noise – we just stood there in our HIV Positive t-shirts with our posters. After about 30 minutes, the security ...

ITPC SPOTLIGHT

View all +
ITPC and KeNPUD: Working together to protect the health and rights of PUDs in Kenya

ITPC and KeNPUD: Working together to protect the health and rights of PUDs in Kenya

In 2013, the International Treatment Preparedness Coalition (ITPC), through Bridging the Gaps, supported KeNPUD with a small grant to grow their organization. Mid-way through their ITPC grant, KeNPUD has conducted 15 advocacy actions, conseled 85 people, and held HIV education workshops for over 200 people. They continue to do health outreach to mobilize people to know their rights.

Watch Video
Civil Society Opposes Patent Application on HIV Drug Truvada® In a Bid to Stop Argentina From Paying 30 Times More Than Other Countries

April 14, 2015

Civil Society Opposes Patent Application on HIV Drug Truvada® In a Bid to Stop Argentina From Paying 30 Times More Than Other Countries

FOR IMMEDIATE RELEASE

The International Treatment Preparedness Coalition (ITPC) supports the patent pre-grant opposition that was filed on 13 April 2015 by the Fundación Grupo Efecto Positivo (FGEP) and the Argentinian Network of Positive People (Redar Positive). The patent was filed at Argentina’s patent office and challenges the validity of a patent application submitted by Gilead Sciences on the anti-HIV combination of tenofovir (TDF) + emtricitabine (FTC).

Known under its trademark name as Truvada®, this medicine is listed by World Health Organization (WHO) among preferred antiretrovirals for treatment of HIV infection. Truvada® is recommended as a key drug to prevent HIV transmission among key populations who are at higher risk of infection. Although the drug is widely available at an affordable price ...

Donate Now